CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
acamprosatedrug
Likely dose
acamprosate 333mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00571103
NCT00571103Phase 4Completed
CompareCT.gov

Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling

University of Iowa·interventional·Posted Dec 11, 2007·Updated May 25, 2017

In Brief

A Phase 4 clinical trial evaluating acamprosate for Pathological Gambling. Completed, enrolled 26 participants.

Detailed Summary

The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPathological Gambling
Countries--
CollaboratorsUniversity of Nebraska, Forest Laboratories

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 11, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.6 years ago

Interventions

acamprosatedrug

Two 333mg tablets taken three times daily.